cabazitaxel

P2, N=96, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed

P2, N=223, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial completion date: Apr 2026 --> Apr 2028

These findings suggest that CBZ induces G2/M cell cycle arrest and caspase-dependent apoptosis through tubulin stabilisation and suppresses tumour progression in vivo. CBZ represents a promising therapeutic candidate for canine LCAL.

P3, N=670, Recruiting, AstraZeneca

P2, N=61, Completed, Masonic Cancer Center, University of Minnesota | Active, not recruiting --> Completed | N=22 --> 61

Herein, we developed a membrane-coated Cabazitaxel (Cab)@TA-Fe³⁺ nanoplatform for enhanced PCa therapy...These combined effects enhance tumor cell death. Overall, this study demonstrates that Cab@TA-Fe³⁺ nanoparticles significantly improve anticancer efficacy by integrating microtubule inhibition and ferroptosis induction, providing a promising strategy for prostate cancer treatment.

Notably, the treatments altered the gene expression of several tumorigenic and immunologic mediators, including MSXI, ZRSR2, GALNTL6, IL24, and IL18R1, which may impact cancer cell behavior. In conclusion, these in vitro findings indicate that the combination of cabazitaxel with VK3 is more effective in inhibiting prostate cancer cell growth than either agent alone and provide exploratory mechanistic insight into their effects on cancer cell metabolism and gene expression.

P3, N=707, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting

The taxane family of compounds, including paclitaxel, docetaxel (Taxotere), and cabazitaxel (Jevtana), are common drugs used in chemotherapy for the frontline treatment of most major types of cancer. 7. Summary and prospective.

We report on the randomized portion of the phase 2, open-label CheckMate 650 trial (NCT02985957), in which docetaxel-experienced, biologically male patients with chemotherapy-refractory metastatic castration-resistant prostate cancer were randomized 2:2:1:2 to nivolumab 3 mg /kg plus ipilimumab 1 mg /kg (n = 73), nivolumab 1 mg /kg plus ipilimumab 3 mg /kg (n = 74), ipilimumab 3 mg /kg (n = 38), or cabazitaxel (n = 74). Preliminary post hoc biomarker analyses in patients who received treatment with any immunotherapy regimen (i.e., treated with either of the nivolumab plus ipilimumab regimens or with ipilimumab alone, n = 12) identified a transcriptional signature, derived from the most highly expressed genes across cell types within select perivascular immune niches (comprising CD31+ endothelial, CD14+HLA-DR+ myeloid, and CD4+ and CD8+ T cells), which was associated with prolonged overall survival. These results provide further evidence of antitumor activity with nivolumab plus ipilimumab in select patients with metastatic castration-resistant prostate cancer and nominate a candidate prognostic biomarker that warrants confirmation in future prospective clinical trials.

P3, N=675, Recruiting, Amgen | Active, not recruiting --> Recruiting

A combined ensemble binary classifier generated through XGBoost integrating these feature sets to predict docetaxel response outperformed models derived from any single feature set, achieving a training area-under-the-ROC curve of 0.87. Pre-cabazitaxel specimens, representing a docetaxel-resistant population, were used for external validation, with a concordance of 79.6% for predicting non-response.